Xention Siphons Off OAB Therapy Into New Spin Out, Provesica
This article was originally published in The Pink Sheet Daily
Atrial fibrillation will be Xention's focus following the spin-out of its overactive bladder assets into a new company, Provesica
You may also be interested in...
New spin-out Ario Pharma is targeting idiopathic cough and cough associated with COPD for Phase II studies of its TRPV1 ion channel antagonist, supported by $3 million in financing from VCs in the U.S. and Europe.
First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.
The $170 million up-front that Abbott Laboratories ponied up for PanGenetics BV's Phase I PG110 anti-nerve growth factor antibody would rank as the largest down-payment ever for a Phase I project. But even though at first glance the mid-November deal resembles an alliance, it is in fact the acquisition of part of PanGenetics itself, and reveals founding investor Index Ventures' intriguing asset-focused strategy.